Pharmacology of stone disease.
Kidney stone disease remains a major health and economic burden on the nation. It has been increasingly recognized that nephrolithiasis can be both a chronic or systemic illness. There have been major limitations in the development of new drugs for the prevention and management of this disease, largely due to our lack of understanding of the complex pathophysiologic mechanisms involving the interaction of three major target organs: the kidney, bone, and intestine. We also do not yet understand the molecular genetic basis of this polygenic disorder. These limitations are coupled with the incorrect perception that kidney stone disease is solely an acute illness, and the lack of reliable tests to assess outcome measures. All of these factors combined have diminished the willingness of the pharmaceutical industry to engage in the development of novel drugs.
Sakhaee
Khashayar
K
Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390-8885, USA. Khashayar.sakhaee@utsouthwestern.edu
D000468:Alkalies / Q000627:therapeutic use*; D000493:Allopurinol / Q000627:therapeutic use*; D000818:Animals; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D053040:Nephrolithiasis / Q000188:drug therapy*; D049993:Sodium Chloride Symporter Inhibitors / Q000627:therapeutic use*
D000468:Alkalies; D004791:Enzyme Inhibitors; D049993:Sodium Chloride Symporter Inhibitors; D000493:Allopurinol